Suppr超能文献

人C1抑制剂反应位点的CpG突变

CpG mutations in the reactive site of human C1 inhibitor.

作者信息

Skriver K, Radziejewska E, Silbermann J A, Donaldson V H, Bock S C

机构信息

Department of Microbiology/Immunology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140.

出版信息

J Biol Chem. 1989 Feb 25;264(6):3066-71.

PMID:2563376
Abstract

C1 inhibitor plays an important role in the regulation of vascular permeability through its ability to inactivate enzymes which release polypeptide kinins. Dysfunctional C1 inhibitor molecules are present in the plasma of affected members of the Da and Ri hereditary angioneurotic edema kindreds. We constructed genomic libraries from Da and Ri patient DNAs which had been cleaved with BclI to generate a fragment containing 21 kilobases of the C1 inhibitor locus. C1 inhibitor gene-containing recombinants originating from mutant Da and Ri alleles were differentiated from those derived from normal alleles by linkage analysis using the intragenic HgiAI restriction fragment length polymorphism. Nucleotide sequencing of the complete protein-coding regions of the mutant alleles identified two different mutations in a CpG dinucleotide corresponding to the first two bases of arginine codon 444. These single base mutations changed the identity of the functionally critical P1 reactive site residue from arginine to cysteine (Da) or histidine (Ri). The additional cysteine residue in C1 inhibitor Da suggests how it is covalently bound to albumin in plasma. The presence of CpG dinucleotides in the codons specifying the P1 arginines of C1 inhibitor and antithrombin III explains the high incidence of histidine and cysteine substitutions observed among dysfunctional mutants of these serine protease inhibitors.

摘要

C1抑制剂通过其使释放多肽激肽的酶失活的能力,在调节血管通透性方面发挥重要作用。功能失调的C1抑制剂分子存在于Da和Ri遗传性血管性水肿家族受影响成员的血浆中。我们从Da和Ri患者的DNA构建了基因组文库,这些DNA已用BclI切割,以产生一个包含21千碱基C1抑制剂基因座的片段。通过使用基因内HgiAI限制性片段长度多态性的连锁分析,将源自突变Da和Ri等位基因的含C1抑制剂基因的重组体与源自正常等位基因的重组体区分开来。对突变等位基因完整蛋白质编码区的核苷酸测序,在对应于精氨酸密码子444前两个碱基的一个CpG二核苷酸中鉴定出两个不同的突变。这些单碱基突变将功能关键的P1反应位点残基的身份从精氨酸改变为半胱氨酸(Da)或组氨酸(Ri)。C1抑制剂Da中额外的半胱氨酸残基表明了它在血浆中与白蛋白共价结合的方式。在指定C1抑制剂和抗凝血酶III的P1精氨酸的密码子中存在CpG二核苷酸,解释了在这些丝氨酸蛋白酶抑制剂的功能失调突变体中观察到的组氨酸和半胱氨酸取代的高发生率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验